Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
lestaurtinib · 1 trial · 2 indications
| Arm | Type | Description |
|---|---|---|
| lestaurtinib | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| lestaurtinib | DRUG | 60 mg bid - 120 mg bid for an 18 weeks (126 days) treatment duration |
Inclusion Criteria: * The patient has polycythemia vera (PV) or essential thrombocytosis (ET). * The patient has a detectable JAK2 V617F mutation. * Patients with PV have at least 1 of the following risk factors: 1. neutrophil count greater than 7000/mm3 2. receiving hydroxyurea treatment * Pa...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Protagonist Therapeutics, Inc. | PTGX | 2 | PHASE3 | Rusfertide |
| Merck & Co., Inc. | MRK | 1 | PHASE3 | Bomedemstat |
| Disc Medicine, Inc. | IRON | 1 | PHASE2 | DISC-3405 |
| Prelude Therapeutics, Inc. | PRLD | 1 | PHASE1 | PRT12396 |
| Novartis AG Sponsored ADR | NVS | 1 | - | Undisclosed |
Lestaurtinib is an investigational small molecule being studied for the treatment of polycythemia vera, a hematologic condition. It has completed a Phase 2 clinical trial in patients with polycythemia vera or essential thrombocytosis. The drug is not approved and remains in clinical development.
Lestaurtinib is a small molecule that targets specific molecular pathways involved in hematologic malignancies. In the context of polycythemia vera, it is being evaluated for its ability to modulate disease-related signaling. The drug is administered orally and has been studied in a biomarker-selected patient population.
Lestaurtinib is being developed by Teva Pharmaceutical Industries Limited, a company publicly traded under the ticker symbol TEVA. The drug is currently in Phase 2 clinical development for polycythemia vera and has not yet received regulatory approval.
Lestaurtinib is in Phase 2 clinical development for polycythemia vera. It has completed one Phase 2 trial, which was an open-label, uncontrolled study. The drug is investigational and has not been approved by regulatory authorities for any indication.
Lestaurtinib has been studied in a completed Phase 2 clinical trial identified as NCT00586651. This open-label study enrolled 39 patients with polycythemia vera or essential thrombocytosis in the United States. The trial was uncontrolled and did not use randomization or blinding.
Yes, lestaurtinib is also known as CEP-701. The clinical trial NCT00586651, which evaluated the drug in patients with polycythemia vera or essential thrombocytosis, was titled as a study of oral CEP-701 (lestaurtinib). Both names refer to the same investigational compound.